

Male Hypogonadism Market by Therapy {Testosterone Replacement Therapy and Gonadotropin & Gonadotropin-Releasing Hormones Therapy [Luteinizing Hormone (LH)], Follicle-Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), and Gonadotropin-Releasing Hormone (GnRH)}, Drug Delivery (Topical Gels, Injectable, Transdermal Patches, and Others), and Type (Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, and Others) - Global Opportunity Analysis and Industry Forecast, 2014-2022

<https://marketpublishers.com/r/M3B81A6BFA8EN.html>

Date: February 2017

Pages: 157

Price: US\$ 4,432.00 (Single User License)

ID: M3B81A6BFA8EN

Abstracts

Male hypogonadism is a medical condition characterized by the inability of the testes to produce sufficient amount of testosterone, which is responsible for the development of secondary sexual characteristics. This results in underdevelopment of muscles, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice.

The global male hypogonadism market was valued at \$2,594 million in 2015, and is estimated to reach \$3,233 million by 2022, growing at a CAGR of 3.1% during the analysis period. Globally, the prevalence for hypogonadism among men is on a rise at a rapid rate, and according to multiple studies, only 10–15% of patients receive treatment for this condition. Major factors that drive the market growth include high incidence of hypogonadism; rise in geriatric population; growth in awareness of hypogonadism & its treatment options; and increased risk of developing hypogonadism due to increased incidence of chronic lifestyle diseases such as diabetes and obesity. In March 2015,

FDA issued cautions & warnings against use of testosterone products as a therapy, and ordered the manufacturers to change labels & add cautions on their packaging. From recent studies conducted by the FDA, there is a high risk of acquiring cardiovascular diseases due to the use of TRT, thus impeding the market growth during the forecast period. However, novel treatment options that are under developmental stage have shown positive results in terms of efficacy, and they are expected to have lesser or no side effects. Therefore, these advancements are anticipated to provide new opportunities in the future.

The global male hypogonadism market is segmented based on therapy, drug delivery, type, and geography. Based on therapy, it is bifurcated into testosterone replacement therapy (TRT), and gonadotropin and gonadotropin-releasing hormones therapy. Gonadotropin and gonadotropin-releasing hormones therapy is further sub-classified into LH, FSH, human chorionic gonadotropin (hCG), and GnRH. Based on drug delivery, it is classified into topical gels, injectables, transdermal patches, and others. Based on type, it is categorized into Klinefelter's syndrome, Kallmann syndrome, pituitary disorders, and others. Based on geography, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).

MALE HYPOGONADISM MARKET @KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market, with current trends and future estimations to elucidate the imminent investment pockets.

It presents a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.

Extensive analysis by therapy helps in understanding the various types of therapies used for the treatment of hypogonadism.

Comprehensive analysis of geographical regions is provided, which helps in determining the prevailing opportunities in these geographies.

Key players within the market are profiled and their strategies are analyzed thoroughly to determine competitive outlook of the global market.

MALE HYPOGONADISM MARKET @KEY MARKET SEGMENTS BY THERAPY

Testosterone Replacement Therapy

Gonadotropin and Gonadotropin-Releasing Hormones Therapy

Luteinizing Hormone (LH)

Follicle-Stimulating Hormone (FSH)

Human Chorionic Gonadotropin (hCG)

Gonadotropin-Releasing Hormone (GnRH)

BY DRUG DELIVERY

Topical Gels

Injectables

Transdermal Patches

Others

BY TYPE

Klinefelter's Syndrome

Kallmann Syndrome

Pituitary Disorders

Others

BY GEOGRAPHY

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Rest of Europe

Asia-Pacific

Japan

India

China

Rest of Asia-Pacific

LAMEA

Latin America

Middle East

Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT

AbbVie Inc.

Allergan plc

Astrazeneca plc

Bayer AG.

Eli Lilly and Company Ltd.

Endo International plc.

Merck & Co., Inc.

Ferring

Finox Biotech

IBSA Institut Biochimique SA

Laboratoires Genevrier

Teva Pharmaceutical Industries Ltd.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

Lipocine Inc.

Pfizer Inc.

Aytu Biosciences

Diurnal Group PLC

Hyundai Pharmaceuticals Co Ltd.

Perrigo Company plc

Novus Biologicals, LLC

Contents

CHAPTER: 1 INTRODUCTION

- 1.1. REPORT DESCRIPTION
- 1.2. KEY BENEFITS
- 1.3. KEY MARKET SEGMENTS
- 1.4. RESEARCH METHODOLOGY
 - 1.4.1. Secondary research
 - 1.4.2. Primary research
 - 1.4.3. Analyst tools and models

CHAPTER: 2 EXECUTIVE SUMMARY

- 2.1. KEY FINDINGS OF THE STUDY
- 2.2. CXO PERSPECTIVE

CHAPTER: 3 MARKET OVERVIEW

- 3.1. MARKET DEFINITION AND SCOPE
- 3.2. KEY FINDINGS
 - 3.2.1. Top investment pockets
 - 3.2.2. Top winning strategies
- 3.3. PORTERS FIVE FORCES ANALYSIS
 - 3.3.1. Bargaining power of buyers
 - 3.3.2. Bargaining power of suppliers
 - 3.3.3. Threat of substitutes
 - 3.3.4. Threat of new entrants
 - 3.3.5. Competitive rivalry
- 3.4. TOP PLAYER POSITIONING, 2015
- 3.5. PATIENTS/PREVALENCE OVERVIEW
- 3.6. MARKET DYNAMICS
 - 3.6.1. Drivers
 - 3.6.1.1. High risk of hypogonadism in geriatric population
 - 3.6.1.2. Lifestyle issues
 - 3.6.1.3. Rise in infertility rates
 - 3.6.1.4. Increased awareness level lead to market growth
 - 3.6.2. Restraints
 - 3.6.2.1. Cautions & warnings issued by FDA against the side effects of TRT

- 3.6.2.2. Social taboos
- 3.6.3. Opportunity
 - 3.6.3.1. Technological advancements

CHAPTER: 4 MALE HYPOGONADISM MARKET, BY THERAPY

4.1. OVERVIEW

- 4.1.1. Market size and forecast

4.2. TESTOSTERONE REPLACEMENT THERAPY

- 4.2.1. Key market trends
- 4.2.2. Key growth factors and opportunities
- 4.2.3. Market size & forecast

4.3. GONADOTROPIN AND GONADOTROPIN RELEASING HORMONES THERAPY

- 4.3.1. Key market trends
- 4.3.2. Key growth factors and opportunities
- 4.3.3. Market size & forecast
- 4.3.4. LH
 - 4.3.4.1. LH market size and forecast
- 4.3.5. FSH
 - 4.3.5.1. FSH market size and forecast
- 4.3.6. hCG
 - 4.3.6.1. hCG market size and forecast
- 4.3.7. Gonadotropin-releasing hormone
 - 4.3.7.1. GnRH market size and forecast

CHAPTER: 5 MALE HYPOGONADISM MARKET, BY DRUG DELIVERY

5.1. OVERVIEW

- 5.1.1. Market size and forecast

5.2. TOPICAL GELS

- 5.2.1. Market size and forecast

5.3. INJECTABLES

- 5.3.1. Market size and forecast

5.4. TRANSDERMAL PATCHES

- 5.4.1. Market size and forecast

5.5. OTHERS

- 5.5.1. Market size and forecast

CHAPTER: 6 MALE HYPOGONADISM MARKET, BY TYPE

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. KLINEFELTERS SYNDROME

6.2.1. Market size and forecast

6.3. PITUITARY DISORDERS

6.3.1. Market size and forecast

6.4. KALLMANN SYNDROME

6.4.1. Market size and forecast

6.5. OTHER

6.5.1. Market size and forecast

CHAPTER: 7 MALE HYPOGONADISM MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends

7.2.2. Key growth factors and opportunities

7.2.3. Market size and forecast

7.2.4. U.S. market size and forecast

7.2.5. Canada market size and forecast

7.2.6. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends

7.3.2. Key growth factors and opportunities

7.3.3. Market size and forecast

7.3.4. Germany market size and forecast

7.3.5. France market size and forecast

7.3.6. UK market size and forecast

7.3.7. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends

7.4.2. Key growth factors and opportunities

7.4.3. Market size and forecast

7.4.4. China market size and forecast

7.4.5. Japan market size and forecast

7.4.6. India market size and forecast

7.4.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

- 7.5.1. Key market trends
- 7.5.2. Key growth factors and Opportunities
- 7.5.3. Market size and forecast
- 7.5.4. Latin America market size and forecast
- 7.5.5. Middle East market size and forecast
- 7.5.6. Africa market size and forecast

CHAPTER: 8 COMPANY PROFILES

8.1. ABBVIE INC.

- 8.1.1. Company overview
- 8.1.2. Company snapshot
- 8.1.3. Operating business segments
- 8.1.4. Business performance

8.2. ALLERGAN, PLC

- 8.2.1. Company overview
- 8.2.2. Company snapshot
- 8.2.3. Operating business segments
- 8.2.4. Business performance
- 8.2.5. Key strategic moves and developments

8.3. ASTRAZENECA PLC.

- 8.3.1. Company overview
- 8.3.2. Company snapshot
- 8.3.3. Operating business segments
- 8.3.4. Business performance

8.4. BAYER AG

- 8.4.1. Company overview
- 8.4.2. Company snapshot
- 8.4.3. Operating business segment
- 8.4.4. Business performance

8.5. ELI LILLY AND COMPANY LIMITED

- 8.5.1. Company overview
- 8.5.2. Company snapshot
- 8.5.3. Operating business segments
- 8.5.4. Business performance
- 8.5.5. Key strategic moves and developments

8.6. ENDO INTERNATIONAL PLC.

- 8.6.1. Company overview

- 8.6.2. Company snapshot
- 8.6.3. Operating business segments
- 8.6.4. Business performance
- 8.6.5. Key strategic moves and developments
- 8.7. FERRING HOLDING S.A.
 - 8.7.1. Company overview
 - 8.7.2. Company snapshot
 - 8.7.3. Operating business segments
 - 8.7.4. Business performance
 - 8.7.5. Key strategic moves and developments
- 8.8. FINOX BIOTECH (FINOX AG)
 - 8.8.1. Company overview
 - 8.8.2. Company snapshot
 - 8.8.3. Operating business segments
 - 8.8.4. Business performance
 - 8.8.5. Key strategic moves and developments
- 8.9. IBSA INSTITUT BIOCHIMIQUE SA
 - 8.9.1. Company overview
 - 8.9.2. Company snapshot
 - 8.9.3. Operating business segments
 - 8.9.4. Business performance
- 8.10. LABORATOIRES GENEVRIER S.A.
 - 8.10.1. Company overview
 - 8.10.2. Company snapshot
 - 8.10.3. Operating business segments
 - 8.10.4. Business performance
 - 8.10.5. Key strategic moves and developments
- 8.11. MERCK & CO., INC.
 - 8.11.1. Company overview
 - 8.11.2. Company snapshot
 - 8.11.3. Operating business segments
 - 8.11.4. Business performance
- 8.12. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
 - 8.12.1. Company overview
 - 8.12.2. Company snapshot
 - 8.12.3. Operating business segments
 - 8.12.4. Business performance
 - 8.12.5. Key strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 1. MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 (\$MILLION)
TABLE 2. TESTOSTERONE REPLACEMENT THERAPY MARKET, BY GEOGRAPHY, 2014-2022 (\$MILLION)
TABLE 3. GONADOTROPINS AND GONADOTROPINS RELEASING HORMONES THERAPY MARKET, BY GEOGRAPHY, 2014-2022 (\$MILLION)
TABLE 4. MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 (\$MILLION)
TABLE 5. TOPICAL GEL MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 (\$MILLION)
TABLE 6. INJECTABLES MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 (\$MILLION)
TABLE 7. TRANSDERMAL PATCHES MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 (\$MILLION)
TABLE 8. OTHERS MARKET FOR MALE HYPOGONADISM, BY GEOGRAPHY, 2014-2022 (\$MILLION)
TABLE 9. MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 (\$MILLION)
TABLE 10. MALE HYPOGONADISM MARKET FOR KLINEFELTER'S SYNDROME, BY GEOGRAPHY, 2014-2022 (\$MILLION)
TABLE 11. MALE HYPOGONADISM MARKET FOR PITUITARY DISORDERS, BY GEOGRAPHY, 2014-2022 (\$MILLION)
TABLE 12. MALE HYPOGONADISM MARKET FOR KALLMANN SYNDROME, BY GEOGRAPHY 2014-2022 (\$MILLION)
TABLE 13. MALE HYPOGONADISM MARKET FOR OTHER SYNDROMES, BY GEOGRAPHY, 2014-2022 (\$MILLION)
TABLE 14. MALE HYPOGONADISM MARKET, BY REGION, 2014-2022 (\$MILLION)
TABLE 15. NORTH AMERICA MALE HYPOGONADISM MARKET, BY COUNTRY, 2014-2022 (\$MILLION)
TABLE 16. NORTH AMERICA MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 (\$MILLION)
TABLE 17. NORTH AMERICA MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 (\$MILLION)
TABLE 18. NORTH AMERICA MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 (\$MILLION)
TABLE 19. EUROPE MALE HYPOGONADISM MARKET, BY COUNTRY, 2014-2022 (\$MILLION)

TABLE 20. EUROPE MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 (\$MILLION)

TABLE 21. EUROPE MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 (\$MILLION)

TABLE 22. EUROPE MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 (\$MILLION)

TABLE 23. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY COUNTRY, 2014-2022 (\$MILLION)

TABLE 24. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 (\$MILLION)

TABLE 25. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 (\$MILLION)

TABLE 26. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 (\$MILLION)

TABLE 27. LAMEA MALE HYPOGONADISM MARKET, BY COUNTRY, 2014-2022 (\$MILLION)

TABLE 28. LAMEA MALE HYPOGONADISM MARKET, BY THERAPY, 2014-2022 (\$MILLION)

TABLE 29. LAMEA MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2014-2022 (\$MILLION)

TABLE 30. LAMEA MALE HYPOGONADISM MARKET, BY TYPE, 2014-2022 (\$MILLION)

TABLE 31. ABBVIE INC.: COMPANY SNAPSHOT

TABLE 32. ABBVIE INC.: OPERATING SEGMENTS

TABLE 33. ALLERGAN: COMPANY SNAPSHOT

TABLE 34. ALLERGAN: OPERATING SEGMENTS

TABLE 35. ASTRAZENECA PLC.: COMPANY SNAPSHOT

TABLE 36. ASTRAZENECA PLC.: OPERATING SEGMENTS

TABLE 37. BAYER: COMPANY SNAPSHOT

TABLE 38. BAYER: OPERATING SEGMENTS

TABLE 39. ELI LILLY AND COMPANY LIMITED: COMPANY SNAPSHOT

TABLE 40. ELI LILLY AND COMPANY LIMITED: OPERATING SEGMENTS

TABLE 41. ENDO INTERNATIONAL PLC.: COMPANY SNAPSHOT

TABLE 42. ENDO INTERNATIONAL PLC.: OPERATING SEGMENTS

TABLE 43. FERRING: COMPANY SNAPSHOT

TABLE 44. FERRING: OPERATING SEGMENTS

TABLE 45. FINOX AG: COMPANY SNAPSHOT

TABLE 46. FINOX AG: OPERATING SEGMENTS

TABLE 47. IBSA INSTITUT BIOCHIMIQUE SA: COMPANY SNAPSHOT

TABLE 48. IBSA INSTITUT BIOCHIMIQUE SA: OPERATING SEGMENTS

TABLE 49. LABORATOIRES GENVRIER: COMPANY SNAPSHOT

TABLE 50. LABORATOIRES GENVRIER: OPERATING SEGMENTS

TABLE 51. MERCK: COMPANY SNAPSHOT

TABLE 52. MERCK: OPERATING SEGMENTS

TABLE 53. TEVA PHARMACEUTICAL: COMPANY SNAPSHOT

TABLE 54. TEVA PHARMACEUTICAL: OPERATING SEGMENTS

List Of Figures

LIST OF FIGURES

- FIGURE 1. MALE HYPOGONADISM MARKET SEGMENTATION
- FIGURE 2. TOP INVESTMENT POCKETS IN MALE HYPOGONADISM MARKET
- FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2013-2015
- FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
- FIGURE 5. TOP PLAYER POSITIONING, 2015
- FIGURE 6. PERCENTAGE OF MEN WITH LOW LEVELS OF TOTAL AND BIOAVAILABLE TESTOSTERONE
- FIGURE 7. DECLINING TESTOSTERONE LEVEL WITH INCREASING AGE
- FIGURE 8. PERCENTAGE OF TOTAL POPULATION ABOVE 65 YEARS OF AGE
- FIGURE 9. LH MARKET FOR MALE HYPOGONADISM, 2014-2022 (\$MILLION)
- FIGURE 10. FSH MARKET FOR MALE HYPOGONADISM, 2014-2022 (\$MILLION)
- FIGURE 11. HCG MARKET FOR MALE HYPOGONADISM, 2014-2022 (\$MILLION)
- FIGURE 12. GNRH MARKET FOR MALE HYPOGONADISM, 2014-2022 (\$MILLION)
- FIGURE 13. MALE HYPOGONADISM MARKET SEGMENTATION, BY TYPE
- FIGURE 14. CAUSES OF MALE HYPOGONADISM
- FIGURE 15. U.S. MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 16. CANADA MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 17. MEXICO MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 18. GERMANY MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 19. FRANCE MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 20. UK MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 21. REST OF EUROPE MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 22. CHINA MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 23. JAPAN MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 24. INDIA MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 25. REST OF ASIA-PACIFIC MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 26. LATIN AMERICA MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 27. MIDDLE EAST MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 28. AFRICA MALE HYPOGONADISM MARKET, 2014-2022 (\$MILLION)
- FIGURE 29. ABBVIE INC.: REVENUE, 2013-2015 (\$MILLION)
- FIGURE 30. ABBVIE INC.: REVENUE BY SEGMENT, 2015 (%)

- FIGURE 31. ABBVIE INC.: REVENUE BY GEOGRAPHY, 2015 (%)
- FIGURE 32. ALLERGAN: REVENUE, 2013-2015 (\$MILLION)
- FIGURE 33. ALLERGAN: REVENUE BY BUSINESS SEGMENT, 2015 (%)
- FIGURE 34. ALLERGAN: REVENUE BY GEOGRAPHY, 2015 (%)
- FIGURE 35. ASTRAZENECA PLC.: REVENUE, 2013-2015 (\$MILLION)
- FIGURE 36. ASTRAZENECA PLC.: REVENUE BY GEOGRAPHY, 2015(%)
- FIGURE 37. BAYER: REVENUE, 2013-2015 (\$MILLION)
- FIGURE 38. BAYER: REVENUE BY SEGMENT, 2015 (%)
- FIGURE 39. BAYER: REVENUE BY GEOGRAPHY, 2015(%)
- FIGURE 40. ELI LILLY AND COMPANY LIMITED: REVENUE, 2013-2015 (\$MILLION)
- FIGURE 41. ELI LILLY AND COMPANY LIMITED: REVENUE BY SEGMENT, 2015 (%)
- FIGURE 42. ELI LILLY AND COMPANY LIMITED: REVENUE BY GEOGRAPHY, 2015 (%)
- FIGURE 43. ENDO INTERNATIONAL PLC.: REVENUE, 2013-2015 (\$MILLION)
- FIGURE 44. ENDO INTERNATIONAL PLC.: REVENUE BY SEGMENT, 2015 (%)
- FIGURE 45. ENDO INTERNATIONAL PLC.: REVENUE BY GEOGRAPHY, 2015 (%)
- FIGURE 46. MERCK: REVENUE, 2013-2015 (\$MILLION)
- FIGURE 47. MERCK: REVENUE BY BUSINESS SEGMENT, 2015 (%)
- FIGURE 48. MERCK: REVENUE BY GEOGRAPHY, 2015 (%)
- FIGURE 49. TEVA PHARMACEUTICAL: REVENUE, 2013-2015 (\$MILLION)
- FIGURE 50. TEVA PHARMACEUTICAL: REVENUE BY BUSINESS SEGMENT, 2015 (%)
- FIGURE 51. TEVA PHARMACEUTICAL: REVENUE BY GEOGRAPHY, 2015 (%)

I would like to order

Product name: Male Hypogonadism Market by Therapy {Testosterone Replacement Therapy and Gonadotropin & Gonadotropin-Releasing Hormones Therapy [Luteinizing Hormone (LH)], Follicle-Stimulating Hormone (FSH), Human Chorionic Gonadotropin (hCG), and Gonadotropin-Releasing Hormone (GnRH)}, Drug Delivery (Topical Gels, Injectable, Transdermal Patches, and Others), and Type (Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, and Others) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Product link: <https://marketpublishers.com/r/M3B81A6BFA8EN.html>

Price: US\$ 4,432.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M3B81A6BFA8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970